Erfonrilimab

Summary

Erfonrilimab (CHEMBL4650483) is a phase-3 clinical-stage antibody; indicated across 11 conditions including non-small cell lung carcinoma and pancreatic ductal adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 11 conditions
• Clinical trials: 23

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650483
Name	Erfonrilimab
Type	Antibody
Max phase	3

Also known as: Erfonrilimab, Kn 046, KN-046, Kn046, KN046, ERFONRILIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
pancreatic ductal adenocarcinoma	3	MONDO:0005184	MONDO:0005184
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
esophageal squamous cell carcinoma	2	MONDO:0005580	EFO:0005922
thymic carcinoma	2	MONDO:0006451	EFO:1000576
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
neoplasm	1	MONDO:0005070	EFO:0000616
triple-negative breast carcinoma	1	MONDO:0005494	EFO:0005537
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE2	12
PHASE1/PHASE2	6
PHASE3	2
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04474119	PHASE3	UNKNOWN	KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer
NCT05001724	PHASE2/PHASE3	TERMINATED	KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
NCT05149326	PHASE3	UNKNOWN	KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
NCT05827796	PHASE1/PHASE2	RECRUITING	IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
NCT05985109	PHASE2	RECRUITING	KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
NCT05985707	PHASE2	NOT_YET_RECRUITING	KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
NCT06023758	PHASE2	RECRUITING	Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
NCT06099821	PHASE2	RECRUITING	KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
NCT03838848	PHASE2	TERMINATED	KN046 in Patients With Advanced Non-small Cell Lung Cancer
NCT03872791	PHASE1/PHASE2	COMPLETED	A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
NCT03925870	PHASE2	COMPLETED	KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
NCT03927495	PHASE2	UNKNOWN	KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT04054531	PHASE2	UNKNOWN	Study of KN046 With Chemotherapy in First Line Advanced NSCLC
NCT04469725	PHASE2	TERMINATED	KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
NCT04542837	PHASE2	COMPLETED	The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
NCT04601610	PHASE1/PHASE2	TERMINATED	KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
NCT04612712	PHASE1/PHASE2	TERMINATED	A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
NCT04925947	PHASE2	TERMINATED	A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
NCT04984668	PHASE1/PHASE2	UNKNOWN	A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
NCT05832892	PHASE1/PHASE2	UNKNOWN	Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
NCT06834399	PHASE2	TERMINATED	TATE and KN046 in MCRC
NCT03529526	PHASE1	UNKNOWN	Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors
NCT03733951	PHASE1	COMPLETED	KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).